WO2004017976A1 - Fast dissolving and taste masked oral dosage form comprising sildenafil - Google Patents
Fast dissolving and taste masked oral dosage form comprising sildenafil Download PDFInfo
- Publication number
- WO2004017976A1 WO2004017976A1 PCT/GB2003/003636 GB0303636W WO2004017976A1 WO 2004017976 A1 WO2004017976 A1 WO 2004017976A1 GB 0303636 W GB0303636 W GB 0303636W WO 2004017976 A1 WO2004017976 A1 WO 2004017976A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- sildenafil
- solid dosage
- fast disintegrating
- disintegrating solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
Definitions
- the present invention relates to a fast dissolving and taste masked dosage form comprising a salt of sildenafil.
- these dosage forms can lead to a rapid release of active component, thereby facilitating the increased absorption of certain active ingredients.
- Freeze drying processes have been used to prepare fast disintegrating dosage forms.
- the product obtained is characterised by a highly porous microstructure of the soluble supporting agent (i.e. mannitol, glycine, lactose, gelatins etc.) in which the active is homogeneously dispersed.
- the soluble supporting agent i.e. mannitol, glycine, lactose, gelatins etc.
- this technology produces a product which rapidly disintegrates in water or in the oral cavity, a drawback is represented by the poor physical integrity of its physical structure which severely limits further manufacturing operations such as forming blister packs.
- freeze drying technology in manufacturing such dosage forms is the high production costs because of the lengthy duration of each freeze drying cycle (normally from 24 to 48 hours).
- the complexity of the industrial plants is another important factor which prejudices the large scale use of this technology for the development of rapid disintegrating tablets.
- thermal shocks as a direct consequence of each freeze drying cycle, might physically modify the physical-chemical properties of the outer membrane of microencapsulated particles.
- WO 99/47126 discloses a physiologically acceptable tablet comprising a compressed tablet formulation free of organic solvent residue that rapidly disintegrates when placed in a body cavity, comprising at least one water soluble non-saccharide polymer, the tablet has a crushing strength of between 0.5 kiloponds and 12.0 kiloponds.
- US 5576014 discloses intrabucally dissolving compressed mouldings comprising a saccharide having low mouldability having been granulated with a saccharide having high mouldability.
- the mouldings exhibit quick disintegration and dissolution in the buccal cavity and have an adequate hardness.
- US 6024981 discloses a hard, compressed, rapidly dissolvable dosage form adapted for direct oral dosing comprising an active ingredient and a matrix including a non-direct compression filler and a lubricant, the dosage form being adapted to rapidly dissolve in the mouth of a patient and thereby liberate the active ingredient.
- WO 91/04757 discloses a solid dosage form adapted for direct oral administration to a human patient comprising an effective amount of at least one systemically distributable ingredient in the form of a tablet of a size and shape adapted for direct oral administration to a human patient, comprising at least one water or saliva activated effervescent disintegration agent, the tablet being substantially completely disintegrable upon exposure to water or saliva, and said at least one effervescent disintegration agent being present in an amount which is effective to aid in rapid disintegration of the tablet and to provide a distinct sensation of effervescence upon disintegration of the tablet in the mouth of a human patient.
- US-A-4886669 discloses a water-dispersible tablet comprising: a) microparticles which contain at least one pharmaceutically active substance b) at least one disintegrant and c) a swellable material which is able to generate a high viscosity when coming into contact with water and which is selected from guar gum, xanthan gum, alginates, dextran, pectins, polysaccharides, sodium or calcium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose, which tablet disintegrates rapidly in water forming a homogeneous suspension of high viscosity that can easily be swallowed.
- WO99/44580 discloses a formulation for preparing a fast disintegrating tablet comprising a drug in multiparticulate form, one or more water insoluble excipients, one or more disintegrants; and optionally one or more substantially water soluble excipients, the amount of the ingredients being such as to provide a disintegration time for the tablet in the mouth in the order of seventy five seconds or less. It is stated superior tablet properties can be achieved by choosing appropriate amounts of the ingredients according to the classification shown below: a) insoluble ingredient: this includes the amount of drug either coated or uncoated and the amount of insoluble excipients including the insoluble inorganic salts used as filler diluents (e.g.
- di- or tri-basic calcium phosphate di- or tri-basic calcium phosphate
- organic filler e.g. microcrystalline cellulose
- water insoluble lubricant e.g. magnesium stearate, sodium steary fumarate, stearic acid or glyceryl behenate
- glidant e.g. talc, silicone dioxide etc.
- substantially soluble components e.g. the amount of compression sugars (e.g. lactose), flavouring agents, sweeteners, binders and surfactants etc.
- disintegrant especially super-disintegrant, such as, maize starch or modified starches, cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose.
- the amount of super disintegrant c) should not be excessive and is therefore preferably in the range 0.5 to 30%, more preferably 1 to 20%, most preferably 2 to 15% by weight of tablet.
- US-A-6106861 discloses a rapidly disintergratable multiparticulate tablet which disintegrates in the mouth in less than forty seconds and which comprises an excipient and an active ingredient in the form of microcrystals coated with a coating agent.
- the excipient comprises, with respect to the mass of the tablet, from 3 to 15% by weight of at least one disintegration agent and from 40 to 90% by weight of at least one soluble diluent agent with binding properties consisting of a polyol having less than thirteen carbon atoms, said polyol being either in the directly compressible form which is composed of particles whose average diameter is from 100 to 500 micrometers or in the powder form which is composed of particles whose average diameter is less than 100 micrometers, said polyol being selected from the group consisting of mannitol, xylitol, sorbitol and maltitol, with the proviso that, when only one soluble diluent agent with binding properties is used, it is a polyol in the directly compressible form
- WO00/09090 discloses an orally disintegrable tablet suitable for use in the delivery of at least one active ingredient in the form of microcapsules or powders characterised by between about 10 and about 80% of active ingredient containing microcapsules or powders by weight based on the weight of the tablet, said microcapsules or powder having a particle size ranging from between about 50 to 3,000 microns, an amount of at least one in-mouth viscosity enhancer, which is sufficient to provide a viscous, swallowable, organoleptically acceptable mass containing said microcapsules, within about three minutes when placed in a patient's mouth, said in-mouth viscosity enhancer being selected from the group consisting of methylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, carbopol and silicon dioxide; optionally between 0 and 60% of a rapidly dissolvable sugar or sugar alcohol filler by weight of the tablet selected from the group consisting of sucrose, mannitol, xylitol, lactos
- EP-A-914818 discloses a tablet comprising sugar alcohol or saccharide having an averaging particle diameter of not more than 30 ⁇ m, an active ingredient, and a disintegrant.
- a wet granulation method using purified water, ethanol or the like is used to prepare the tablets in the method, for example, granulation can be executed by means of a general granulator such as a fluid-bed granulator, a rotary stirring granulator or an extruding granulator.
- the granulated material is dried, and mixed with a lubricant, and thereafter compressed into predetermined shape.
- Binder, sour agent, foaming agent, sweetening agent, flavouring agent, or colourant can be added as additive.
- EP 1145711 discloses a flash-melt pharmaceutical dosage form comprising a medicament and a combination of four excipients consisting of a superdisintegrant, a dispersing agent, a distributing agent and a binder.
- the four excipients may be dry granulated with the medicament and suitable conventional ingredients.
- EP 0281200 discloses a pharmaceutical tablet comprising an amphoteric ?- lactam antibiotic, and as disintegrants, a cellulose product and low-substituted hydroxypropylcellulose, in which the cellulose product is microcrystalline or microfine cellulose or a mixture of both.
- the tablet may be formed by compressing a granule of ?-lactam antibiotic and microcrystalline cellulose and/or microfine cellulose.
- WO01/39746 discloses a method for improving the compressibility of a superdisintegrant, comprising causing a partial or complete internal co- transformation of superdisintegrant particles, comprising temporarily opening up said particles and adding an augmenting agent which enhances the properties of the superdisintegrant relative to the unmodified particles of the superdisintegrant.
- the superdisintegrant may be mixed with an active agent and compressed into solid dosage forms or may be subjected to a wet granulation with the active ingredient.
- a fast disintegrating tablet comprising an active ingredient and one or more disintegrants characterised in that the tablet comprises agglomerates having an agglomerated particle size of at least 50 ⁇ m, said agglomerates comprising at least 10% by weight of a superdisintegrant selected from croscarmellose cellulose, crospovidone and sodium starch glycollate and being free of active ingredient.
- the PCT applications further disclose a method of making a fast disintegrating tablet comprising the steps of
- agglomerates having an average agglomerated particle size of at least 50 ⁇ m and comprising one or more superdisintegrants selected from croscarmellose cellulose, crospovidone and sodium starch glycollate such that the agglomerates comprise at least 10% by weight of superdisintegrant and the agglomerates are free of active ingredient
- step (ii) mixing the agglomerates from step (I) with an active ingredient and optionally other tableting excipients, and (iii) compressing the mixture from step (ii) to form a tablet.
- US 6106881 discloses a rapidly disintegratable multiparticulate tablet which disintegrates in the mouth in less than forty seconds and which comprises an excipient and an active ingredient in the form of microcrystals coated with a coating agent.
- US 5876759 provides a compressed pharmaceutical dosage form, comprising: a) at least one coated particle comprising at least one pharmaceutical coated with taste-masking coating comprising a blend of a first polymer selected from a cellulose acetate and cellulose acetate butyrate and a second polymer selected from polyvinyl pyrrolidone and hydroxypropyl cellulose, wherein the weight ratio of the first polymer to the second polymer is within the range of about 90 : 10 to about 50 : 50; b) a water-disintegratable, compressible carbohydrate selected from mannitol, sorbitol, dextrose, xylitol, lactose and mixtures thereof; and c) a binder selected from cellulose, polyvinyl pyrrolidone, starch, modified starch and mixtures thereof, the dosage form having a hardness of about 1.0 to 3.0 kp wherein the carbohydrate disintegrates in the oral cavity within 30 seconds after oral administration thereby allowing said
- Another disadvantage of incorporating coated particles into the fast dissolving dosage form is that the large coated particles can leave an unpleasant gritty mouthfeel within the oral cavity.
- WO 95/11671 discloses the use of an absorbate composition comprising magnesium aluminium silicate and two or more pharmaceutically acceptable actives in a fast dissolving dosage form.
- EP 0582396 discloses a pharmaceutical composition having reduced bitterness relative to the bitterness of its constituent antibiotic agent, the composition comprising an azalide antibiotic, magnesium oxide (as an alkaline earth agent) and a pharmaceutically acceptable carrier.
- the pharmaceutically active ingredients can be incorporated into fast dissolving dosage forms in the granular form.
- US 5464632 provides a method of making a granulate for use in the preparation of mouth-soluble, rapidly disintegrating tablets, which process comprises: a) granulating in a fluid bed: (a) a polyalcohol; (b) an active ingredient; (c) from 1 to 30% of an edible acid wherein the edible acid is not part of an effervescent mixture consisting of an acid and a base; (d) optionally, other solid components selected from lubricants, sweetening agents, and flavours; and (e) an aqueous solution or aqueous dispersion of water soluble or water-dispersible polymer that provides 1-10% of the final weight of granulate; and b) drying the granulate in the fluid bed.
- WO 98/01114 provides a granulate, containing an active ingredient, having a solubility in water of 1>10, in admixture with a water dispersible cellulose, which is a microcrystalline cellulose and sodium carboxymethyl cellulose, in which the water dispersible cellulose is present in an amount of ⁇ 15% wt%, the percentage based on the weight of active ingredient.
- incorporation of polymeric material in the granulation medium can also lead to the delayed release of the active ingredient.
- Sildenafil citrate (1 -[[3-(6,7-dihydro-1 -methyl-7-oxo-3-propyl-1 H-pyrazolo[4,3- d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate) is a pharmaceutically active ingredient useful for the treatment of sexual dysfunction, such as, male erectile dysfunction (ED).
- ED can have a profound effect on the quality of life with subjects often reporting increased anxiety, loss of self-esteem, lack of self-confidence, tension and difficulty in the relationship with their partner.
- the prevalence of ED has been found to be associated with age. Complete ED has an estimated prevalence of 5% in men aged 40 years to 15% at age 70 years.
- sildenafil may benefit from the presentation of a fast disintegrating dosage form for both the geriatric patient group who may have swallowing difficulty and for the improved rate of drug absorption.
- sildenafil citrate has a very strong bitter taste, which renders the administration of fast dissolving dosage form of sildenafil an unpleasant experience.
- WO 00/07596 discloses a pharmaceutical formulation which can be rapidly dissolved in water and which, as an active constituent, contains the phosphodiesterase (PDE) type 5 inhibitor sildenafil or the pharmaceutically safe salts thereof. There is no disclosure as to the mouthfeel and taste properties of the formulation.
- PDE phosphodiesterase
- WO 02/05820A1 provides solid dispersions of sildenafil citrate and certain highly water soluble sugars, which solid dispersions significantly increases the water solubility of sildenafil citrate. This requires a sophisticated process of preparing the solid dispersion.
- US 20020002172A1 provides an orally disintegrating pharmaceutical preparation that comprises sildenafil free base together with a pharmaceutically acceptable carrier.
- the sildenafil free base is said to have very low water solubility and to be virtually taste free.
- a fast dissolving and taste masked sildenafil solid dosage form comprising: i. sildenafil granules which granules comprise at least 45% by weight of a salt of sildenafil, a solubilisation inhibitor for said salt of sildenafil and optionally a sweetening agent and ii. one or more disintegrants wherein the disintegrants or combination of disintegrants are present in the form of agglomerates having an
- the dosage form may additionally comprise one or more of water soluble fillers, diluents, lubricants, sweetening agents, flavouring agents and other auxiliary ingredients.
- the dosage form of the invention rapidly disintegrates in the oral cavity within 30 seconds, preferably within 15 seconds.
- the dosage forms have a pleasing mouth feel and do not have the characteristic bitterness of sildenafil due to the presence of the solubilisation inhibitor. It has been found that in absence of the solubilisation inhibitor the characteristic bitterness of sildenafil cannot simply be masked by a sweetener alone.
- Tablets made according to the invention may have a smooth surface, pleasing mouthfeel that is free of grittiness and disintegrate within thirty seconds, preferably within fifteen seconds according to the standard European Pharmacopoeia disintegration test.
- sildenafil Any pharmaceutically acceptable salt of sildenafil (1-[[3-(6,7-dihydro-1-methyl- 7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4- methylpiperazine
- hydrochloride hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate and tartrate.
- Sildenafil citrate is preferred.
- the salt of sildenafil is generally present in an amount to provide from 5 to 150mg/tablet, preferably 5 to 10Omg/tablet.
- the sildenafil granules can be prepared by any means known in the art, for example, wet granulation, dry granulation, melt extrusion, extrusion- spheronisation, spray drying, co-spray drying, spray agglomeration etc.
- the sildenafil granules contain at least 45% of a suitable salt of sildenafil. Preferably, the sildenafil granules contain at least 55% of a suitable salt of sildenafil. More preferably, the sildenafil granules contain more than 65% of a suitable salt of sildenafil granule.
- sildenafil granules contain a suitable agent that reduces the solubilisation of sildenafil salt.
- Sildenafil citrate has a solubility is 3.5 mg/ml at 23°C in distilled water.
- sildenafil citrate has a solubility profile depending on pH with the maximal solubility of approximately 24 mg/ml at pH2.0. Consequently, an effective method of reducing the solubility of sildenafil is through increased pH in the dissolution medium.
- Any pharmaceutically acceptable pH raising agent is acceptable. Suitable examples include sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium phosphate, sodium citrate, calcium oxide, calcium carbonate, magnesium oxide and magnesium carbonate.
- the preferred pH raising agents are those with buffering capacity such as sodium carbonate, sodium bicarbonate and sodium phosphate.
- Solubilisation inhibitors include those agents that will release the counterion of the sildenafil salt, for example sodium citrate for sildenafil citrate.
- the solubilisation inhibitor is present at a sufficient amount as to form a saturated solution upon the disintegration of the tablet.
- solubilisation inhibitors include those agents that can increase the hydrophobicity of the system, thereby reducing the water available to solubilise the sildenafil salt, for example, glyceryl monostearate, waxes, sodium stearyl lactate etc.
- a sweetening agent can be included in the sildenafil granules.
- suitable sweetening agents include nutritive sweeteners such as sucrose, glucose, fructose, glucose, trehalose, galactose, mannitol, sorbitol, xylitol and intensive sweeteners such as aspartame, acesulfame K, sucrolose and NHDC.
- disintegrant is present in the form of agglomerates.
- disintegrant may be present in non-agglomerated form provided that at least 50%, preferably at least 75%, more preferably at least 90% by weight of disintegrant is agglomerated.
- the agglomerates comprise at least 10%, preferably at least 25%, generally from 25 to 100% by weight disintegrant.
- the remainder of the agglomerates may comprise known tabletting ingredients including water-soluble and water insoluble fillers and/or diluents, active ingredient, binder, flavouring agents etc.
- the agglomerates comprise from 25 to 100% by weight disintegrant, the remainder being a water-soluble filler and optionally a binder, such as citric acid.
- Disintegrating agents suitable for use in the present formulations include pharmaceutical excipients which facilitate the break-up of a tablet when it is placed in aqueous environment. Disintegrants once in contact with water, swell, hydrate, change in volume or form to produce a disruptive force that opposes the efficiency of the binder(s) causing the compressed tablet to break apart. They belong to different morphological classes and possess different functionality properties. A non-limiting list of the different classes of disintegrants or mixtures thereof which can be used in the formulations of the present invention is given below:
- natural starches such as maize starch, potato starch etc.
- directly compressible starches such as starch 1500
- modified starches such as carboxymethylstarches and sodium starch glycolate which are available as PRIMOJEL® and EXPLOTAB ® and EXPLOSOL.
- cross-linked polyvinylpyrrolidones e.g. crospovidones available as e.g. POLYPLASDONE XL® and KOLLIDON XL®.
- modified celluloses such as cross-linked sodium carboxymethylcelluloses available as, e.g., AC-DI-SOL®, PRIMELLOSE®, PHARMACEL XL ®, EXPLOCEL ® and NYMCEL ZSX®.
- Microcrystalline cellulose e.g. AVICEL®, PHARMACEL®, EMCOCELL® and VIVAPUR®.
- Methacrylic acid-divinylbenzene copolymer salts available as e.g. AMBERLITE® IRP-88.
- the agglomerates used in the invention comprise a superdisintegrant selected from:
- crospovidones available as e.g. POLYPLASDONE XL® and KOLLIDON XL®.
- croscarmellose cellulose as, e.g., AC-DI-SOL®, PRIMELLOSE®, PHARMACEL XL ®, EXPLOCEL ® and NYMCEL ZSX®.
- Substantially water-soluble components that may be used in the present invention include sugars or soluble fillers, e.g. lactose, sucrose, dextrose, mannitol, etc., flavouring agents, sweeteners e.g. aspartame, saccharine etc., pH adjusting agents e.g. fumaric acid, citric acid, sodium acetate etc., binders e.g. polyethylene glycols, soluble hydroxyalkylcellulose, polyvinylpyrrolidone, gelatins, natural gums etc., surfactants e.g. sorbitan esters, docusate sodium, sodium lauryl sulphate, cetrimide etc., soluble inorganic salts e.g. sodium carbonate, sodium bicarbonate, sodium chloride etc.
- sugars or soluble fillers e.g. lactose, sucrose, dextrose, mannitol, etc.
- flavouring agents e.g. aspartam
- Substantially water insoluble inorganic excipients include for example, water insoluble fillers and/or diluents, e.g. salts such as dibasic calcium phosphate, calcium phosphate tribasic, calcium sulfate and dicalcium sulfate.
- the particle size of the water insoluble inorganic excipient is such that at least 35% of the particles are larger than 75 ⁇ m. Most preferably at least 80% of the particles are larger than 75 ⁇ m.
- the amount of disintegrant is generally at least 2% by weight of the tablet and preferably at least 4% by weight; a useful range being 4 to 20% by weight. Increasing levels of disintegrant tend to give poorer friability values for the tablet.
- the amount of water-soluble and water-insoluble materials may be selected over wide ranges, depending upon the desired properties of the tablet.
- the agglomeration of the disintegrant may be accomplished by any means known in the art, for example, wet granulation, dry granulation, extrusion, spray drying, co-spray drying, spray agglomeration etc.
- the average particle size of the agglomerator is at least 50 ⁇ m. Increasing particle size decreases disintegration time. Particle size ranges of from 75 to 500 ⁇ m are useful. Larger particle sizes may adversely affect the appearance of the tablets.
- the agglomerates are free of the active ingredient.
- Tablets according to the present invention can be manufactured by well known tableting procedures.
- common tableting processes the agglomerates and other materials are deposited into a cavity, and one or more punch members are then advanced into the cavity and brought into intimate contact with the material to be pressed, whereupon compressive force is applied. The material is thus forced into conformity with the shape of the punches and the cavity.
- Hundreds, and even thousands, of tablets per minute can be produced in this fashion.
- Various tableting methods are comprehensively discussed throughout Pharmaceutical Dosage Forms : Tablets, Second Edition, edited by Herbert A. Lieberman et al., Copyright 1989 by Marcel Dekker, Inc., as well as other well known texts.
- Polyplasdone® XL-10 crospovidone having an average particle size of about 30 ⁇ m
- Mannitol mannitol having an average particle size of about 60 ⁇ m
- Explotab® sodium starch glycolate having an average particle size about 40 ⁇ m
- Disintegration of the tablet was carried out by placing one tablet on the tongue of the subject. The subject was instructed not to bite the tablet but allowed to move the tablet gently within the mouth. The disintegration time was determined as the time between the tablet was placed in the mouth and when the last noticeable granules were disintegrated.
- Sildenafil granules were prepared according to the following formulation:
- sildenafil granule To prepare the sildenafil granule, citric acid and lactitol were dissolved in water. Sildenafil citrate, mannitol SD200 and sodium starch glycolate were blended in a food processor for 10 minutes, the citric acid/lactitol solution was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.
- Agglomerated disintegrant granules were prepared according to the following formulation:
- citric acid and lactitol were dissolved in deionised water, mannitol and polyplasdone were dry mixed for 10 minutes in a food mixer.
- the citric acid/lactitol solution was added to the dry mixture to form wet granules.
- the wet granules were dried in a forced air oven at 50°C to achieve a moisture level of less than 2%.
- the dried granules were screened and the 75 to 250 micron size range was obtained.
- Tableting the sildenafil granules and agglomerated disintegrant granules were placed in a suitable container. Aspartame and lemon flavour were screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Stoke B2 rotary press fitted with 16 stations of 3/8 inch (9.525 mm) normal concave tooling.
- the tablets had an average weight of 252 mg and a mean crushing strength of 1.1 kp.
- the oral disintegration time was 28 seconds with a strong bitter taste which lingered in the mouth for more than 5 minutes.
- sildenafil granule To prepare the sildenafil granule, citric acid and lactitol were dissolved in water. Sildenafil citrate, lemon flavour and aspartame were blended in a food processor for 10 minutes, the citric acid/lactitol solution was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C. Mannitol granules were prepared according to the following formulation.
- citric acid and lactitol were dissolved in deionised water, mannitol and Vivastar were mixed for 10 minutes in a food mixer.
- the citric acid/lactitol solution was added to the dry mixture to form wet granules.
- the wet granules were dried in a forced air oven at 50°C to achieve a moisture level of less than 1%.
- Tableting the sildenafil granules, mannitol granules, agglomerated disintegrant granules were placed in a suitable container. Aspartame and lemon flavour were screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Colton 204 rotary press fitted with 4 stations of 10mm normal concave tooling (chromed).
- the tablets had an average weight of 252.5 mg and a mean crushing strength of 1.1 kp.
- the oral disintegration time was 12 seconds demonstrating the significant improvement in oral disintegration time when concentrated sildenafil granules were incorporated.
- the tablets had a strong bitter taste which lingered in the mouth for more than 5 minutes.
- Sildenafil granules were prepared according to the following formulation:
- sildenafil granules To prepare the sildenafil granules, citric acid and lactitol were dissolved in water. Sildenafil citrate and acesulfame K were blended in a food processor for 10 minutes, the citric acid/lactitol solution was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.
- Mannitol granules were prepared according to Example 2.
- Agglomerated disintegrant granules were prepared according to Example 1.
- Tableting the sildenafil granules, mannitol granules, agglomerated disintegrant granules were placed in a suitable container. Lemon flavour was screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Colton 204 rotary press fitted with 4 stations of 10mm normal concave tooling (chromed).
- the tablets had an average weight of 251.1 mg and a mean crushing strength of 1.4 kp.
- the oral disintegration time was 15 seconds demonstrating the significant improvement in oral disintegration time when concentrated sildenafil granules were incorporated.
- the tablets had a strong bitter taste which lingered in the mouth for more than 5 minutes suggesting that the bitter taste can not be successfully masked by sweetener alone.
- Example 4 (Invention)
- Sildenafil granules were prepared according to the following formulation:
- sildenafil granules To prepare the sildenafil granules, citric acid and lactitol were dissolved in distilled water. Sildenafil citrate, sodium carbonate and acesulfame K were blended in a food processor for 10 minutes, the citric acid/lactitol solution was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.
- Mannitol granules were prepared according to Example 2.
- Agglomerated disintegrant granules were prepared according to Example 1.
- Tableting the sildenafil granules, mannitol granules, agglomerated disintegrant granules were placed in a suitable container. Acesulfame K and lemon flavour was screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Colton 204 rotary press fitted with 4 stations of 10mm normal concave tooling (chromed).
- the tablets had a pleasant sweet taste without the characteristic bitterness of sildenafil demonstrating the taste masking function of sodium carbonate. It was of interest to note that no effervescence was detected within the mouth.
- Sildenafil granules were prepared according to the following formulation:
- sildenafil citrate sodium carbonate and acesulfame K were blended in a food processor for 10 minutes, distilled water was added was added and mixed in, and the resulting wet granules were dried in a tray drier at 50°C.
- Mannitol granules were prepared according to Example 2.
- Agglomerated disintegrant granules were prepared according to Example 1. Tableting: the sildenafil granules, mannitol granules, agglomerated disintegrant granules were placed in a suitable container. Acesulfame K and lemon flavour was screened, added to the mixture and blended for 10 minutes. Magnesium stearate was screened, added to the mixture and blended for a further 2 minutes. Tablets were prepared using a Colton 204 rotary press fitted with 4 stations of 10mm normal concave tooling (chromed).
- the tablets had an average weight of 260.0 mg and a mean hardness of 0.9 kp.
- the oral disintegration time was 10 seconds demonstrating the significant improvement in oral disintegration time when concentrated sildenafil granules were incorporated.
- the tablets had a pleasant sweet taste without the characteristic bitterness of sildenafil demonstrating the taste masking function of sodium carbonate. No effervescence was detected within the oral cavity.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03792490A EP1539173A1 (en) | 2002-08-21 | 2003-08-20 | Fast dissolving and taste masked oral dosage form comprising sildenafil |
JP2004530364A JP2006501233A (en) | 2002-08-21 | 2003-08-20 | Oral dosage form containing sildenafil with fast dissolution and occult taste |
CA002496106A CA2496106A1 (en) | 2002-08-21 | 2003-08-20 | Fast dissolving and taste masked oral dosage form comprising sildenafil |
US10/525,680 US20060100214A1 (en) | 2002-08-21 | 2003-08-20 | Fast dissolving and taste masked oral dosage form comprising sildenafil |
AU2003255822A AU2003255822A1 (en) | 2002-08-21 | 2003-08-20 | Fast dissolving and taste masked oral dosage form comprising sildenafil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0219516.2 | 2002-08-21 | ||
GBGB0219516.2A GB0219516D0 (en) | 2002-08-21 | 2002-08-21 | Fast dissolving and taste masked oral dosage form comprising sildenafil |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004017976A1 true WO2004017976A1 (en) | 2004-03-04 |
Family
ID=9942749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/003636 WO2004017976A1 (en) | 2002-08-21 | 2003-08-20 | Fast dissolving and taste masked oral dosage form comprising sildenafil |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060100214A1 (en) |
EP (1) | EP1539173A1 (en) |
JP (1) | JP2006501233A (en) |
AU (1) | AU2003255822A1 (en) |
CA (1) | CA2496106A1 (en) |
GB (1) | GB0219516D0 (en) |
WO (1) | WO2004017976A1 (en) |
ZA (2) | ZA200501419B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115345A1 (en) * | 2004-05-28 | 2005-12-08 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
WO2007110559A1 (en) * | 2006-03-29 | 2007-10-04 | Pliva Hrvatska D.O.O. | Pharmaceutically acceptable salts and polymorphic forms of sildenafil |
US7390524B1 (en) | 2004-05-20 | 2008-06-24 | Advanced Cardiovascular Systems, Inc. | Method for electrostatic spraying of an abluminal stent surface |
EP1961413A1 (en) * | 2005-07-22 | 2008-08-27 | Mitsubishi Tanabe Pharma Corporation | Rapidly disintegratable oral tablet |
JP2008546786A (en) * | 2005-06-23 | 2008-12-25 | シェーリング コーポレイション | Rapidly absorbable oral formulation of PDE5 inhibitor |
DE102009016584A1 (en) | 2009-04-06 | 2010-10-07 | Ratiopharm Gmbh | Orodispersible tablet containing a sildenafil salt |
WO2011030351A3 (en) * | 2009-09-03 | 2011-06-30 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
US8097292B2 (en) | 2004-04-27 | 2012-01-17 | Advanced Cardiovascular Systems, Inc, | Methods for electrostatic coating of an abluminal stent surface |
US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
WO2013077533A1 (en) * | 2011-11-25 | 2013-05-30 | 한국유나이티드제약 주식회사 | Chewable sildenafil citrate tablets in which bitterness is masked, and production method therefor |
KR101304343B1 (en) * | 2006-04-06 | 2013-09-11 | 한미사이언스 주식회사 | Fast dissolving oral formulation of pde-5 inhibitors |
US8613950B2 (en) | 2005-03-01 | 2013-12-24 | Bayer Intellectual Property Gmbh | Pharmaceutical forms with improved pharmacokinetic properties |
US8663684B2 (en) | 2008-09-19 | 2014-03-04 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Lactose and cellulose-based tableting aid |
WO2014092358A1 (en) * | 2012-12-14 | 2014-06-19 | Hanmi Pharm. Co., Ltd. | Chewable tablet comprising a phosphodiesterase-5 inhibitor |
US20140271847A1 (en) * | 2013-03-13 | 2014-09-18 | SatisPharma, LLC | Formulations and methods for rapid penile erections |
US8841446B2 (en) | 2002-07-16 | 2014-09-23 | Bayer Intellectual Property Gmbh | Medicaments containing vardenafil hydrochloride trihydrate |
US9757455B2 (en) | 2005-11-28 | 2017-09-12 | Johnson & Johnson Consumer Inc. | Oral therapeutic compound delivery system |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
AU2007264418B2 (en) | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
AU2010239082B2 (en) * | 2009-04-24 | 2014-10-16 | Iceutica Pty Ltd | A novel formulation of metaxalone |
EP2338474A1 (en) * | 2009-12-23 | 2011-06-29 | Ratiopharm GmbH | Fusion tablet containing compacted sildenafil base |
EP2588088A4 (en) * | 2010-07-02 | 2014-05-07 | Fmc Corp Inc | Solid forms |
TWI462739B (en) * | 2010-11-02 | 2014-12-01 | Univ Kaohsiung Medical | Processes for preparing piperazinium salts of sildenafil-analogues and use thereof |
JP5883687B2 (en) * | 2011-03-09 | 2016-03-15 | 第一三共ヘルスケア株式会社 | Pharmaceutical composition containing a PDE5 inhibitor |
JP5941558B2 (en) * | 2012-02-28 | 2016-06-29 | 株式会社ソウル製薬Seoul Pharma. Co., Ltd. | High content fast dissolving film containing sildenafil as an active ingredient and concealing bitterness |
CN113456604B (en) * | 2021-07-08 | 2022-12-20 | 天地恒一制药股份有限公司 | Sildenafil citrate orally disintegrating tablet and preparation method thereof |
CN114028348B (en) * | 2021-10-09 | 2022-11-08 | 南京长澳医药科技有限公司 | Sildenafil citrate orally disintegrating tablet and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007596A1 (en) * | 1998-07-31 | 2000-02-17 | Hexal Ag | Water-soluble pharmaceutical formulation for administering sildenafil |
WO2002020058A1 (en) * | 2000-09-06 | 2002-03-14 | Tanabe Seiyaku Co., Ltd. | Preparations for oral administration |
WO2003072084A1 (en) * | 2002-02-28 | 2003-09-04 | Phoqus Pharmaceuticals Limited | Fast disintegrating tablets |
-
2002
- 2002-08-21 GB GBGB0219516.2A patent/GB0219516D0/en not_active Ceased
-
2003
- 2003-08-20 EP EP03792490A patent/EP1539173A1/en not_active Withdrawn
- 2003-08-20 ZA ZA200501419A patent/ZA200501419B/en unknown
- 2003-08-20 US US10/525,680 patent/US20060100214A1/en not_active Abandoned
- 2003-08-20 WO PCT/GB2003/003636 patent/WO2004017976A1/en not_active Application Discontinuation
- 2003-08-20 AU AU2003255822A patent/AU2003255822A1/en not_active Abandoned
- 2003-08-20 JP JP2004530364A patent/JP2006501233A/en active Pending
- 2003-08-20 CA CA002496106A patent/CA2496106A1/en not_active Abandoned
-
2005
- 2005-02-17 ZA ZA200501420A patent/ZA200501420B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007596A1 (en) * | 1998-07-31 | 2000-02-17 | Hexal Ag | Water-soluble pharmaceutical formulation for administering sildenafil |
WO2002020058A1 (en) * | 2000-09-06 | 2002-03-14 | Tanabe Seiyaku Co., Ltd. | Preparations for oral administration |
WO2003072084A1 (en) * | 2002-02-28 | 2003-09-04 | Phoqus Pharmaceuticals Limited | Fast disintegrating tablets |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841446B2 (en) | 2002-07-16 | 2014-09-23 | Bayer Intellectual Property Gmbh | Medicaments containing vardenafil hydrochloride trihydrate |
US8097292B2 (en) | 2004-04-27 | 2012-01-17 | Advanced Cardiovascular Systems, Inc, | Methods for electrostatic coating of an abluminal stent surface |
US7390524B1 (en) | 2004-05-20 | 2008-06-24 | Advanced Cardiovascular Systems, Inc. | Method for electrostatic spraying of an abluminal stent surface |
EP3216445A1 (en) | 2004-05-28 | 2017-09-13 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
AU2005247048B2 (en) * | 2004-05-28 | 2007-12-13 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
WO2005115345A1 (en) * | 2004-05-28 | 2005-12-08 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
US8613950B2 (en) | 2005-03-01 | 2013-12-24 | Bayer Intellectual Property Gmbh | Pharmaceutical forms with improved pharmacokinetic properties |
JP2008546786A (en) * | 2005-06-23 | 2008-12-25 | シェーリング コーポレイション | Rapidly absorbable oral formulation of PDE5 inhibitor |
EP1961413A1 (en) * | 2005-07-22 | 2008-08-27 | Mitsubishi Tanabe Pharma Corporation | Rapidly disintegratable oral tablet |
EP1961413A4 (en) * | 2005-07-22 | 2012-07-11 | Mitsubishi Tanabe Pharma Corp | Rapidly disintegratable oral tablet |
EP3449928A1 (en) | 2005-11-28 | 2019-03-06 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
EP3263117A1 (en) | 2005-11-28 | 2018-01-03 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
US9757455B2 (en) | 2005-11-28 | 2017-09-12 | Johnson & Johnson Consumer Inc. | Oral therapeutic compound delivery system |
WO2007110559A1 (en) * | 2006-03-29 | 2007-10-04 | Pliva Hrvatska D.O.O. | Pharmaceutically acceptable salts and polymorphic forms of sildenafil |
KR101304343B1 (en) * | 2006-04-06 | 2013-09-11 | 한미사이언스 주식회사 | Fast dissolving oral formulation of pde-5 inhibitors |
US8663684B2 (en) | 2008-09-19 | 2014-03-04 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Lactose and cellulose-based tableting aid |
DE102009016584A1 (en) | 2009-04-06 | 2010-10-07 | Ratiopharm Gmbh | Orodispersible tablet containing a sildenafil salt |
WO2010115576A1 (en) | 2009-04-06 | 2010-10-14 | Ratiopharm Gmbh | Melting tablet containing a sildenafil salt |
WO2011030351A3 (en) * | 2009-09-03 | 2011-06-30 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
WO2013077533A1 (en) * | 2011-11-25 | 2013-05-30 | 한국유나이티드제약 주식회사 | Chewable sildenafil citrate tablets in which bitterness is masked, and production method therefor |
WO2014092358A1 (en) * | 2012-12-14 | 2014-06-19 | Hanmi Pharm. Co., Ltd. | Chewable tablet comprising a phosphodiesterase-5 inhibitor |
US20140271847A1 (en) * | 2013-03-13 | 2014-09-18 | SatisPharma, LLC | Formulations and methods for rapid penile erections |
Also Published As
Publication number | Publication date |
---|---|
AU2003255822A1 (en) | 2004-03-11 |
CA2496106A1 (en) | 2004-03-04 |
ZA200501419B (en) | 2006-10-25 |
GB0219516D0 (en) | 2002-10-02 |
EP1539173A1 (en) | 2005-06-15 |
JP2006501233A (en) | 2006-01-12 |
US20060100214A1 (en) | 2006-05-11 |
ZA200501420B (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060100214A1 (en) | Fast dissolving and taste masked oral dosage form comprising sildenafil | |
US11013762B1 (en) | Pharmaceutical compositions | |
US20050169986A1 (en) | Fast disintegrating tablets | |
US20060099250A1 (en) | Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets | |
JP5209492B2 (en) | Pharmaceutical formulations for the production of fast-disintegrating tablets | |
US8153161B2 (en) | Medicament-containing particle and a solid preparation containing the particle | |
JP2010529074A (en) | Pharmaceutical formulations for the production of fast-disintegrating tablets | |
JP2010529072A (en) | Pharmaceutical formulations for the production of fast-disintegrating tablets | |
EP1773292B1 (en) | Rapidly disintegrating orodispersible composition containing nonfilamentous coprocessed polyols particles and silicified microcrystalline cellulose | |
HU227360B1 (en) | Quickly decomposing pharmaceutical composition containing tramadol or a tramadol salt | |
JP2004175796A (en) | Intraoral disintegrating preparation for treating dysuria | |
US20110014286A1 (en) | Mixture for producing rapidly disintegrating tablets | |
JP2002255796A (en) | Rapidly disintegrating tablet in oral cavity and method for producing the same | |
JP2002029964A (en) | Solid medicine composition | |
WO2004089343A1 (en) | Water soluble tablets | |
EP2593081B1 (en) | Ferrimannitol-ovalbumin tablet composition | |
Dixena et al. | Superdisintegrant current status and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2496106 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/01419 Country of ref document: ZA Ref document number: 200501419 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003255822 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004530364 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003792490 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003792490 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006100214 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10525680 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10525680 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003792490 Country of ref document: EP |